Safety of Tirofiban in Acute Ischemic Stroke: The SaTIS Trial

Background and Purpose— Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time. Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials. Safety and efficacy in patients with ischemic stroke are uncertain. This was addressed in the Safety of Tirofiban in acute Ischemic Stroke (SaTIS) trial. Methods— Two hundred sixty patients with acute ischemic stroke were randomized in a placebo-controlled, prospective, open-label treatment, blinded outcome reading multicenter trial. Subjects with a National Institutes of Health Stroke Scale between 4 and 18 received intravenously either tirofiban or placebo within 3 to 22 hours after symptom onset for 48 hours. The primary end point was the rate of cerebral bleeding as measured in follow-up CT scans 2 to 7 days after inclusion. The secondary end point was clinical efficacy within 1 week (National Institutes of Health Stroke Scale, modified Rankin Scale) and after 5 months (Barthel Index, modified Rankin Scale). Results— The rate of cerebral hemorrhagic transformation (I/II) and parenchymal hemorrhage (I/II) did not differ between both groups (tirofiban 36 of 120; placebo 33 of 124: OR, 1.18; 95% CI, 0.66 to 2.06). Mortality after 5 months was significantly lower in patients treated with tirofiban (3 of 130 [2.3%] versus 11 of 126 [8.7%]; OR, 4.05; 95% CI, 1.1 to 14.9). No difference in neurological/functional outcome was found after 1 week and after 5 months. Conclusions— We conclude that tirofiban might be safe in acute moderate ischemic stroke even when administered within a large time window after symptom onset and might save lives in the late outcome. Clinical Trial Registration— URL: www.strokecenter.org/trials/. Trial name: SaTIS. Enrollment began before July 1, 2005.

[1]  Joanna Wardlaw,et al.  Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial , 2009, The Lancet Neurology.

[2]  H. Zeumer,et al.  Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature. , 2009, Stroke.

[3]  C. Imray,et al.  Transcranial Doppler ultrasonography‐directed intravenous glycoprotein IIb/IIIa receptor antagonist therapy to control transient cerebral microemboli before and after carotid endarterectomy , 2008, The British journal of surgery.

[4]  A. Carter,et al.  The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.

[5]  W. Hacke,et al.  Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II) , 2008, Stroke.

[6]  S. Steinhubl,et al.  Effects of Unfractionated Heparin and Glycoprotein IIb/IIIa Antagonists Versus Bivalirdin on Myeloperoxidase Release From Neutrophils , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  G. Stoll,et al.  Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding , 2007, Circulation.

[8]  C. Molina.  Monitoring and imaging the clot during systemic thrombolysis in stroke patients , 2007, Expert review of cardiovascular therapy.

[9]  M. Hennerici,et al.  Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial , 2006, The Lancet.

[10]  K. Alexander,et al.  Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative , 2006, Circulation.

[11]  A. Divani,et al.  Intracranial Hemorrhages Associated with Intravenous Platelet Glycoprotein IIB/IIIA Receptor Inhibitors in the United States , 2005, Cardiovascular Drugs and Therapy.

[12]  Abciximab Emergent Stroke Treatment Trial Investigators,et al.  Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial , 2005, Stroke.

[13]  M. Chopp,et al.  Analysis of Combined Treatment of Embolic Stroke in Rat with r-tPA and a GPIIb/IIIa Inhibitor , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  J. Fullard.  The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. , 2004, Current pharmaceutical design.

[15]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[16]  R. Seitz,et al.  Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion , 2004, Stroke.

[17]  A. Qureshi,et al.  Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. , 2004, AJNR. American journal of neuroradiology.

[18]  M. Chopp,et al.  Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke , 2003, Circulation.

[19]  M. Siebler,et al.  Cerebral Microembolism Is Blocked by Tirofiban, a Selective Nonpeptide Platelet Glycoprotein IIb/IIIa Receptor Antagonist , 2003, Circulation.

[20]  E. Topol,et al.  Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up , 2002, Circulation.

[21]  GötzThomalla,et al.  Acute Basilar Artery Occlusion Treated With Combined Intravenous Abciximab and Intra-arterial Tissue Plasminogen Activator , 2002 .

[22]  G. Thomalla,et al.  Acute Basilar Artery Occlusion Treated With Combined Intravenous Abciximab and Intra-arterial Tissue Plasminogen Activator: Report of 3 Cases , 2002, Stroke.

[23]  G. Fink,et al.  Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban , 2002, Neurology.

[24]  H. Link,et al.  Non-TH1 cytokines are augmented systematically early in Guillain–Barré syndrome , 2002 .

[25]  H. Freund,et al.  Bleeding Risk of Tirofiban, a Nonpeptide GPIIb/IIIa Platelet Receptor Antagonist in Progressive Stroke: An Open Pilot Study , 2001, Cerebrovascular Diseases.

[26]  D. Kondziolka.  Fetal cell implantation to treat Parkinson's disease: questions for the future. , 2001, Neurosurgery.

[27]  W. Hacke,et al.  Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic? , 2001, Stroke.

[28]  A. Shuaib,et al.  Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab')2 in a model of focal cerebral ischemia in rats. , 2001, Journal of neurosurgery.

[29]  C. Bode,et al.  Augmented Platelet Aggregation as Predictor of Reocclusion after Thrombolysis in Acute Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[30]  E. Connolly,et al.  Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. , 1998, The Journal of clinical investigation.

[31]  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.